Mohammad Shadid

Mohammad Shadid is a PhD and MBA holder with extensive experience in the pharmaceutical industry. Mohammad began their career at Takeda Pharmaceuticals in 2008 as a Scientist in Drug Metabolism & Pharmacokinetics (DMPK). During their tenure, they managed all discovery biotransformation and drug metabolism studies, led the design and implementation of the first ADC biotransformation assays, and was nominated and awarded the Takeda Star award by Head of Oncology Division in 2013. In 2016, they moved to Biogen as a DMPK Lead, where they served as the DMPK representative on the only internal Biogen CNS asset that was filed for an IND in 2017-2018 and provided PK, PK/PD, and all other ADME support. In 2018, they joined Sarepta Therapeutics as Translational Development Lead and Nonclinical Development Lead, where they were accountable for all preclinical ADME, PK/PD, in vivo pharmacology, and M&S study designs. Mohammad also led the nonclinical sub-team for Sarepta's second generation platform. In 2021, they moved to Aruvant as Executive Director and Head of Nonclinical Development and Senior Director-Nonclinical Development. In this role, they were accountable for Aruvant's nonclinical strategy to support IND-enabling studies and CMC comparability for the CD-34 stem cell and AAV programs. Mohammad also developed the biomarkers and bioanalytical assay strategy to support clinical translation and oversaw the development and validation of +15 assays within one year. In 2023, they joined Korro Bio, Inc. as Vice President of Translational Sciences.

Overall, Mohammad Shadid has worked in the pharmaceutical industry for over 15 years, gaining experience in drug metabolism & pharmacokinetics, preclinical ADME, PK/PD, in vivo pharmacology, M&S study designs, biomarkers and bioanalytical assay strategy, and nonclinical strategy.

Mohammad Shadid has a diverse educational background. Mohammad obtained an Applied Chemistry degree from Jordan University of Science and Technology. Mohammad then went on to pursue a Masters in Organic Chemistry from Middle Tennessee State University (MTSU). Following this, they obtained a Master of Business Administration (MBA) from Cornell Johnson Graduate School of Management, with a focus on Strategy and General Management. Finally, they completed their education with a Ph.D in Drug Metabolism and Pharmacokinetics from the University of Utah. Additionally, they have obtained four certifications from LinkedIn, including Unconscious Bias (2020), Getting Your Ideas Approved (2018), Project Management: Calculating Earned Value (2018), and Scrum: The Basics (2018).